EQ

Equillium
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.780
-0.020
-0.71%
Closed 16:00 07/02 EDT
OPEN
2.792
PREV CLOSE
2.800
HIGH
2.820
LOW
2.711
VOLUME
25.26K
TURNOVER
--
52 WEEK HIGH
6.14
52 WEEK LOW
2.200
MARKET CAP
49.16M
P/E (TTM)
-1.7630
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average EQ stock price target is 17.00 with a high estimate of 22.00 and a low estimate of 14.00.

EPS

EQ News

More
Equillium to Present at Jefferies Virtual Healthcare Conference
LA JOLLA, Calif., May 21, 2020 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products.
GlobeNewswire · 05/21 20:07
Equillium Q1 EPS $(0.450) Down From $(0.340) YoY
Equillium (NASDAQ:EQ) reported quarterly losses of $(0.450) per share. This is a 32.35 percent decrease over losses of $(0.340) per share from the same period last year.
Benzinga · 05/13 20:13
Equillium Reports First Quarter 2020 Financial Results
LA JOLLA, Calif., May 13, 2020 -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to.
GlobeNewswire · 05/13 20:07
Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
GlobeNewswire · 05/07 21:07
Equillium Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital
GlobeNewswire · 03/30 21:07
Equillium Reports $15M Common Stock Offering With Lincoln Park Capital
Benzinga · 03/30 20:13
Equillium EPS misses by $0.05
seekingalpha · 03/27 01:19
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
GlobeNewswire · 03/26 21:07

Industry

Pharmaceuticals
+0.58%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About EQ

Equillium, Inc. is a biotechnology company. The Company develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. EQ001, disease modifying treatment for multiple severe immuno-inflammatory disorders. It plans to initiate a Phase Ib/II clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD.
More

Webull offers kinds of Equillium Inc stock information, including NASDAQ:EQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EQ stock methods without spending real money on the virtual paper trading platform.